Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults
暂无分享,去创建一个
T. Bousema | J. Aponte | G. van Gemert | M. M. Jore | R. Sauerwein | C. King | C. Ockenhouse | P. Pickkers | Yimin Wu | K. Teelen | R. ter Heine | J. Ramjith | M. G. van de Vegte-Bolmer | M. McCall | A. Birkett | E. Locke | K. Miura | Shwu-Maan Lee | S. V. van Beek | Saskia C. van der Boor | M. Smit | Morolayo A. Ayorinde | M. van de Vegte-Bolmer